MSN Pharma concludes USFDA audit with zero observations
Hyderabad: MSN Pharmaceuticals Inc. (MSNPI), a wholly-owned subsidiary of MSN Group of Companies, based out of Piscataway, New Jersey, USA has successfully completed its maiden USFDA audit with zero observations.
The state-of-the-art finished dosages facility was established to bolster MSN Group's product portfolio as well as Contract Development & Manufacturing services, in the US and several other key regulatory markets.
"This is a major accomplishment for us. It augments the core strategy of establishing ourselves as a preferred Contract Development & Manufacturing Service provider globally, offering endto-end drug manufacturing services. Also, besides helping us to deepen our presence in the US market, it will enable us to make high-quality generics affordable and accessible to the patients swiftly and efficiently," MSN Group commented.
Read also: MSN Labs gets USFDA nod for generic version of Cangrelor in India
Founded in 2003, MSN Group is the research-based pharmaceutical companies based out of Hyderabad, India. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof.
Read also: Dr Reddys, MSN Labs launch of generic Empagliflozin may lead to court battle
